Data / Drug companies / Aurobindo Pharma Limited
Aurobindo Pharma Limited: 102 products in the FDA NDC directory, labeler code 84386
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Aurobindo Pharma Limited (labeler code 84386) lists 102 products in the FDA National Drug Code Directory, covering 19 finished drugs by generic name. By type: 45 prescription drugs, 40 bulk ingredients. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 26, 2026.
The request: Watch Aurobindo Pharma Limited (FDA labeler code 84386): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 84386
- Products in commercial distribution
- 102
- Packages
- 163
- Finished drugs by generic name
- 19
- Prescription products
- 45
- Over the counter products
- 4
- Controlled substance products
- Schedule III 6, Schedule IV 2, Schedule V 6
- Flagged as original packager
- 27 of 27 products that carry the flag
- Started marketing in the last 12 months
- 75
- Earliest marketing start
- January 22, 2024
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 48 | 47.1% |
| Bulk ingredients | 40 | 39.2% |
| Drugs for further processing | 13 | 12.7% |
| Authorized generics (NDA) | 1 | 1% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 45 | 44.1% |
| Bulk ingredients | 40 | 39.2% |
| Drugs for further processing | 13 | 12.7% |
| Over the counter drugs | 4 | 3.9% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Perampanel | 6 | 6 |
| Brivaracetam | 5 | 17 |
| Pravastatin sodium | 5 | 39 |
| Sacubitril and valsartan | 3 | 29 |
| Fluoxetine | 3 | 42 |
| Cinacalcet | 3 | 18 |
| Benazepril hydrochloride | 3 | 24 |
| Sertraline hydrochloride | 3 | 55 |
| Isotretinoin | 3 | 16 |
| Tizanidine | 2 | 38 |
| Cilostazol | 2 | 10 |
| Diclofenac sodium | 2 | 109 |
| Rasagiline | 2 | 11 |
| Loperamide hydrochloride | 1 | 82 |
| Polyethylene glycol 3350 | 1 | 67 |
| Loratadine | 1 | 125 |
| Permethrin | 1 | 12 |
| Alfuzosin hydrochloride | 1 | 13 |
| Baclofen | 1 | 65 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Powder | 40 | 39.2% |
| Tablet, film coated | 35 | 34.3% |
| Tablet | 15 | 14.7% |
| Powder, for solution | 3 | 2.9% |
| Capsule | 3 | 2.9% |
| Granule | 2 | 2% |
| Tablet, film coated, extended release | 2 | 2% |
| Gel | 1 | 1% |
| Cream | 1 | 1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Sacubitril and Valsartan | 84386-083 | Tablet, film coated | Generic drugs (ANDA) | October 26, 2026 |
| Sacubitril and Valsartan | 84386-082 | Tablet, film coated | Generic drugs (ANDA) | October 26, 2026 |
| Sacubitril and Valsartan | 84386-081 | Tablet, film coated | Generic drugs (ANDA) | October 26, 2026 |
| Rasagiline | 84386-170 | Tablet | Generic drugs (ANDA) | October 20, 2026 |
| Rasagiline | 84386-169 | Tablet | Generic drugs (ANDA) | October 20, 2026 |
| Canagliflozin hemihydrate (process-ii) | 84386-234 | Powder | Bulk ingredients | October 12, 2026 |
| Perampanel | 84386-089 | Tablet, film coated | Generic drugs (ANDA) | October 2, 2026 |
| Perampanel | 84386-088 | Tablet, film coated | Generic drugs (ANDA) | October 2, 2026 |
| Perampanel | 84386-087 | Tablet, film coated | Generic drugs (ANDA) | October 2, 2026 |
| Perampanel | 84386-086 | Tablet, film coated | Generic drugs (ANDA) | October 2, 2026 |
| Perampanel | 84386-085 | Tablet, film coated | Generic drugs (ANDA) | October 2, 2026 |
| Perampanel | 84386-084 | Tablet, film coated | Generic drugs (ANDA) | October 2, 2026 |
| Polyethylene glycol 3350 | 84386-150 | Powder, for solution | Drugs for further processing | September 28, 2026 |
| Auropap 90f (acetaminophen directly compressible granules) process-ii | 84386-233 | Granule | Drugs for further processing | September 16, 2026 |
| Isotretinoin | 84386-011 | Capsule | Generic drugs (ANDA) | September 10, 2026 |
| Isotretinoin | 84386-010 | Capsule | Generic drugs (ANDA) | September 10, 2026 |
| Isotretinoin | 84386-009 | Capsule | Generic drugs (ANDA) | September 10, 2026 |
| Pravastatin sodium | 84386-167 | Tablet | Generic drugs (ANDA) | September 4, 2026 |
| Cilostazol | 84386-003 | Tablet | Generic drugs (ANDA) | September 3, 2026 |
| Cilostazol | 84386-002 | Tablet | Generic drugs (ANDA) | September 3, 2026 |
| Tizanidine | 84386-024 | Tablet | Generic drugs (ANDA) | September 1, 2026 |
| Tizanidine | 84386-023 | Tablet | Generic drugs (ANDA) | September 1, 2026 |
| Trofinetide | 84386-217 | Powder | Bulk ingredients | August 5, 2026 |
| Atenolol | 84386-219 | Powder | Bulk ingredients | July 31, 2026 |
| Sparsentan | 84386-218 | Powder | Bulk ingredients | July 31, 2026 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.